Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

What's new in renal cell cancer research? Highlights of GU-ASCO 2014.

ABSTRACT: One of the major areas of research presented at the 2014 Genitourinary Cancers Symposium (GU-ASCO 2014) pertained to the management of renal cell cancer (RCC). The following pages provide a summary of some of the most important presentations and posters presented during the 3-day symposium.

SUBMITTER: Kapoor A

PROVIDER: S-EPMC4001680 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

What's new in renal cell cancer research? Highlights of GU-ASCO 2014.

Kapoor Anil A

Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20140301 3-4 Suppl 2

One of the major areas of research presented at the 2014 Genitourinary Cancers Symposium (GU-ASCO 2014) pertained to the management of renal cell cancer (RCC). The following pages provide a summary of some of the most important presentations and posters presented during the 3-day symposium. ...[more]

PMID: 24860631

Similar Datasets

Kidney Cancer Research Highlights from ASCO GU 2022 Meeting.

Project description: Not available

| S-EPMC9272854 | biostudies-literature

Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting.

Project description:The 2022 American Society of Clinical Oncology (ASCO) annual meeting was held June 3-7, 2022, in Chicago, Illinois. This hybrid meeting gathered international cancer experts across multidisciplinary specialties and was held both virtually and in-person. Here, we highlight key kidney cancer research updates presented at the meeting. Slides from the meeting's presentations are available on the ASCO meeting library website.

| S-EPMC9725101 | biostudies-literature

Neues aus der Urologie von GU-ASCO, ASCO und EAU

Project description: Not available

| S-EPMC7651824 | biostudies-literature

ASCO 2018 highlights: metastatic breast cancer.

Project description:This article reviews the clinically most relevant presentations at the American Society of Clinical Oncology (ASCO) annual meeting 2018 on the topic of metastatic breast cancer. In the randomized placebo-controlled phase 3 trial MONALEESA-3, testing ribociclib vs. placebo in combination with fulvestrant in postmenopausal women or men with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (ABC), an increase of median progression-free survival (PFS) from 12.8 months to 20.5 months by the addition of the CDK4/6 inhibitor was reported (HR 0.59; P > 0.01). Taselisib, an alpha specific PI3K inhibitor, was tested in combination with fulvestrant in pretreated HR+/HER2- ABC patients with PIK3CA mutations in the placebo-controlled phase 3 trial SANDPIPER. PFS was significantly longer (7.4 months vs 5.4 months; HR 0.70, P < 0.01) but severe adverse events were more frequent (32% and 9%) in the taselisib group. In triple-negative breast cancer, the AKT inhibitor capivasertib (AZD5363) was combined with paclitaxel as first-line treatment in the placebo-controlled phase 2 trial PAKT. In patients with altered PIK3CA, AKT1 or PTEN, median PFS increased from 3.7 months to 9.3 months (HR 0.30; two-sided P = 0.01). No treatment effect was shown in the non-altered group. The most common adverse events attributed to capivasertib were diarrhea, fatigue and stomatitis. Results of two phase I trials of trastuzumab antibody-drug conjugates (ADCs) indicated HER2 as a non-oncogenic surface target in breast cancer patients expressing HER2.

| S-EPMC6280779 | biostudies-literature

ASCO 2016: highlights in breast cancer.

Project description:At the 2016 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented. MA17.R was the first randomized phase III trial to evaluate the prolongation of adjuvant aromatase-inhibitor (AI) therapy from 5 to 10 years; while a significant reduction of disease-free survival events was observed in the extended treatment group, the absolute difference was relatively small and longer endocrine therapy resulted in a higher fracture rate. A combined analysis of three North American trials emphasized the superiority of anthracycline containing adjuvant chemotherapy regimens compared with docetaxel/cyclophosphamide (TC), while the PANTHER trial investigated dose-dense tailored adjuvant treatment. In metastatic breast cancer, the main interest was on cyclin-dependent kinase (CDK) 4/6 inhibitors. In PALOMA-2, the addition of palbociclib to letrozole prolonged progression-free survival (PFS) from 14.5 to 24.8 months resulting in the longest PFS data ever reported in the first-line setting. A subgroup analysis of premenopausal patients accrued to PALOMA-3 indicated that in this patient subset, ovarian function suppression plus fulvestrant and palbociclib yielded results comparable to the postmenopausal population. ESR1 mutations were another focus of interest as these activating mutations in the gene coding for the estrogen receptor alpha apparently evolve under the selection pressure of AI therapy.

| S-EPMC5165027 | biostudies-literature

Tourette Syndrome research highlights 2014.

Project description:About 200 journal articles reported research on Tourette syndrome and other tic disorders in 2014. Here we briefly summarize a few of the reports that seemed most important or interesting, ranging from animal models to human studies. Readers can comment on our choices or provide their own favorites using the tools on the online article.

| S-EPMC4602330 | biostudies-literature

ASCO 2018: highlights of urothelial cancer and prostate cancer.

Project description:Prostate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year's ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium-223 dose escalation study concluded that the currently used dose with 6 cycles of 55?kBq/kg remains the standard of care. The PARP inhibitor olaparib plus abiraterone provided a significant benefit in radiological progression-free survival compared with abiraterone alone, independent of homologous recombination repair (HRR) mutation status. In localized muscle-invasive urothelial carcinoma, two phase II trials (ABACUS and PURE-01) exploring the pathological complete remission rate of atezolizumab and pembrolizumab prior to cystectomy in cisplatin-unfit or cisplatin-fit patients are presented. Novel targeted therapies such as fibroblast growth factor receptor (FGFR) inhibitors or monoclonal antibodies against nectin-4 confirmed astonishing objective response rates in heavily pretreated metastatic urothelial carcinoma (mUC) patients, resulting in a median overall survival (OS) up to 13.8 months. Finally, updated 1?year and 2?year OS survival rates of pembrolizumab and atezolizumab in the first line setting of mUC are presented.

| S-EPMC6280775 | biostudies-literature

What's new in FGF23 research?

Project description:FGF23 is a hormone that regulates phosphate and vitamin D metabolism by binding to Klotho-fibroblast growth factor (FGF) receptor complex. Excess actions of FGF23 cause several kinds of hypophosphatemic diseases. The mechanism of overproduction of FGF23 in some of these diseases is becoming clear, whereas it is not yet completely understood. Several specific methods to inhibit FGF23 actions have been reported as candidates for new therapies for these FGF23-related hypophosphatemic diseases. On the other hand, many epidemiological studies indicated the association between high FGF23 levels and several adverse events in cardiovascular system, kidney, bone and mortality. FGF23 was recently shown to induce ventricular hypertrophy in a Klotho-independent manner. However, it is not yet shown whether this Klotho-independent action of FGF23 can explain all the results of epidemiological studies.

| S-EPMC3727838 | biostudies-other

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.

Project description:Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

| S-EPMC8381132 | biostudies-literature

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer.

Project description:Following coverage by The ASCO Post, Jennifer L. Glass, PA-C, MS, of the Mayo Clinic dives into the major findings in prostate cancer from the 2019 ASCO Annual Meeting in Chicago and their implications for advanced practitioners.

| S-EPMC7520735 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data